Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | METAP1 | P53582 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251842 | 0.89 | MAOB (0.54) | MAOBMETAP1CYP19A1MAPK14NPC1 | |
| SCHEMBL29392039 | 0.89 | MAOB (0.54) | MAOBMETAP1CYP19A1MAPK14NPC1 | |
| SCHEMBL6130607 | 0.86 | MAPK14 (0.56) | MAOBMETAP1CYP19A1MAPK14 | |
| SCHEMBL1512575 | 0.84 | METAP1 (0.70) | MAOBMETAP1ALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL5337855 | 0.83 | MAPK14 (0.67) | MAOBMETAP1CYP19A1MAPK14NPC1 | |
| Butane SCHEMBL4688097 | 0.83 | BRD4 (0.52) | MAOBMETAP1CYP19A1MAPK14ACHE | |
| SCHEMBL21469311 | 0.83 | MAOB (0.56) | MAOBMETAP1CYP19A1MAPK14NPC1 | |
| SCHEMBL268592 | 0.81 | KDM4E (0.56) | MAOBMETAP1CYP19A1ALDH1A1LMNA | |
| Acetic Acid SCHEMBL6934641 | 0.81 | MAOB (0.51) | MAOBMETAP1CYP19A1MAPK14NPC1 | |
| Water SCHEMBL28454486 | 0.80 | KDM4E (0.54) | MAOBMETAP1CYP19A1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | MAOB 216/4885METAP1 596/4885CYP19A1 3511/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | MAOB 333/4885METAP1 1434/4885CYP19A1 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.